Efficacy and Safety of BLV 2 or 10 mg for 96 Weeks in CHD Including in 2 Patients With HIV/HBV/HDV
Background: Bulevirtide (BLV) is a first-in-class, entry inhibitor, approved in the EU for the treatment of chronic hepatitis D. Limited data exists on the safety and efficacy of BLV in HIV/HBV/HDV coinfection. The aim of this Week (W) 96 analysis from the Phase 3 MYR301 (NCT03852719) study is to describe the safety and efficacy of…